Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Madharry who wrote (1125)	5/20/2001 11:48:53 AM
From: Icebrg	Read Replies (1) of 1298

Madharry My guess would be somewhere between 200 and 400 mUSD. CEGEs current market capitalization is 615 mUSD, which is not "bad". The current value of cash and the ABGX-shares are really not of interest, when evaluating the company. A better question would be to ask how much that will remain when the company has brought GVAX to the market. Take that figure, discount it back to current value and add to this say 200 mUSD for the vaccine program and you could perhaps have an indication of what the company "should" be worth today. I don't think the gene therapy IP represents any major values today. The company does definitively keep a very low profile, as far as they are concerned. As reference points one could perhaps use two other cancer vaccine companies, which I believe are not flush with cash. GZMO with a market cap. of 197 mUSD and BIOM with 361 m USD. Ice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next